The Surgical Outcomes of Limbal Allograft Transplantation in Eyes Having Limbal Stem Cell Deficiency

Muhammet Derda Ozer1, Emre Altnkurt2, Yusuf Cem Yilmaz3, Ali Ceyhun Gedik4, Nilufer Alparslan5

1Department of Ophthalmology, Medical Faculty, Van Yuzuncu Yil University, Van, Turkey, 2Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 3Department of Ophthalmology, Agri State Hospital, Agri, Turkey, 4Department of Ophthalmology, Luleburgaz State Hospital, Kirkareli, Turkey, 5Private Practice, Istanbul, Turkey

Abstract

Purpose: To report the limbal allograft transplantation and penetrating keratoplasty (PK) results in limbal stem cell deficiency (LSCD)-developed eyes because of chemical or thermal injury.

Methods: Medical records of 18 eyes of 14 patients who had undergone keratolimbal allograft (KLAL) or living-related conjunctival limbal allograft (lr-CLAL) with or without PK and followed up at least 1 year postoperatively were evaluated retrospectively. The preoperative LSCD grade was noted in all patients. Rejection incidents, recurrence of LSCD, and corneal graft clarity along with a visual improvement during the follow-up were noted. The complications rate due to surgery or injury itself, for instance, glaucoma and cataract, were evaluated. The limbal allograft tissue survival analysis and corneal allograft survival analysis were done to reveal the differences in both the procedures. The existence of normal corneal epithelium and improvement in visual acuity were accepted as the surgical success criteria.

Results: In the limbal allograft transplantation group, the survival rates of the allograft tissue were 65 ± 10.7% at 1 year and 36.6 ± 11.4% at 3 years in lr-CLAL and 66.7 ± 15.7% at 12 months and 53.3 ± 17.3% at 18 months in KLAL-transplanted eyes. The survival rate of corneal allograft at the 5th postoperative year was lower in the simultaneous procedure compared to the staged procedure, but it was not statistically significant (25.7 ± 25.8% vs. 62.5 ± 17.1%, P = 0.75). The ambulatory vision was achieved in 10 eyes (56%) after a mean follow-up time of 93.8 ± 37.8 months. The visual acuity level has increased in 12 eyes (67%) after the last follow-up, and there was not any significant difference between the KLAL and lr-CLAL.

Conclusions: Ocular surface integrity was longer in KLAL than in lr-CLAL transplantation, but it was not statistically significant. The staged procedure was more convenient than the simultaneous procedure in terms of corneal allograft clarity maintenance in limbal allograft-employed eyes.

Keywords: Allograft limbal transplantation, Chemical injury, Limbal stem cell deficiency, Penetrating keratoplasty

INTRODUCTION

To maintain corneal clarity, the integrity of the corneal epithelium is crucial.1 The corneal epithelium originates from the limbal stem cells located in the limbus.1 Limbal stem cells are ultimately responsible for the renewal and regeneration of the corneal epithelium.2 A decrease in the number of limbal stem cells due to ocular surface injury leads to the corneal opacity and scar development.3 In such cases, if the limbal stem cell deficiency (LSCD) is not appropriately adjusted before corneal transplantation, it may not be possible to maintain the clarity of the transplanted corneal graft. Therefore, it is possible...
to treat such cases with limbal stem cell transplantation (LSCT) on or with cultivated limbal epithelial transplantation (CLET) to the donor site.4,8

After Thoft and friend’s suggestion of the XYZ hypothesis related to the regeneration of corneal epithelium, various up-to-date ocular surface transplantation techniques have emerged and have improved the management and prognosis of LSCD.9 Limbal autograft and allograft transplantation can restore depleted limbal stem cell population, and normal corneal phenotype can be reestablished.7 If only one eye is affected and the fellow eye is healthy, then successful reconstruction can be achieved by transplanting autologous limbal epithelial stem cells from the fellow eye.10‑14 However, when total LSCD involves both the eyes, an allogeneic source of limbal epithelial stem cells is required for the corneal surface reconstruction. This can be achieved by a living-related conjunctival limbal allograft (lr‑CLAL) or keratolimbal allograft (KLAL) from cadaveric donors.5,8,15‑17 The survival of allogeneic limbal epithelial stem cells depends on systemic immunosuppression. Despite immunosuppressive treatment with systemic cyclosporin A, the success rate of lr‑CLAL and KLAL is not long-lasting.18‑24

In LSCT, many methods have been recently developed that allow the acquisition of smaller allografts to overcome the potential risk of LSCD development in the donor’s eye.25,26 In one method, both autologous and allogeneic CLET (auto‑CLET and allo‑CLET) involve harvesting a small portion of a limbal graft and augmenting it in a culture. In another method, simple limbal epithelial transplantation (SLET) involves harvesting a 2 mm × 2 mm limbal graft and dividing it into small pieces to enhance the proliferation and migration of limbal stem cells.25 Both the techniques require a transport substrate (ammonium transport [AMT]); however, their superiority over the established techniques is controversial.27,33

In this study, we report our experience on the limbal allograft transplantation with and without penetrating keratoplasty (PK). We follow up challenges and long-term outcomes of a group of patients who have LSCD due to chemical or thermal ocular surface injury. The long-term results of the sequentially or simultaneously applied PK results of lr‑CLAL- or KLAL-transplanted eyes are evaluated in this study.

**METHODS**

Retrospective medical records of patients who underwent conjunctival allograft and KLAL transplantation with or without PK between November 1995 and January 2014 in Istanbul University, Faculty of Medicine, Ophthalmology Department, Istanbul, Turkey, were reviewed. The study was approved by Istanbul University, Istanbul Faculty of Medicine, Surgical and Pharmaceutical Research Ethics Board. Informed consent was not required due to the retrospective nature of the study.

Patients who had LSCT due to LSCD and followed up at least 1 year postoperatively were involved in the study.

Conjunctivalization is defined as conjunctival epithelium with a vascular component encroaching over the corneal surface along with the existence of irregular corneal epithelium by fluorescein staining under the biomicroscopic examination. Conjunctivalization was decided to be the diagnostic criteria of LSCD. Additional criteria in defining LSCD were the absence of limbal palisades of Vogt, the presence of superficial neovascularization on the cornea, and the presence of goblet cells on the corneal surface in the impression cytology24 [Figure 1]. Cases that were followed up <1 year postoperatively were excluded from the study.

The best corrected visual acuities, biomicroscopic findings, intraocular pressures (IOPs), and fundoscopic findings of all the participants were evaluated and recorded. The cases in which a fundoscopic examination could not be possible were evaluated using a B‑scan ultrasonography. The patients who applied to the clinic 4 months after the injury incident were classified as the chronic group and those who applied within 4 months after the accident were classified as the acute group. In the first visit of the acute group patients, it was decided to wait and treat with topical medications and/or amniotic membrane transplantation until the inflammation subsided. For the initial visit of the chronic group patients, existing lid problems, tear film instability, and chronic inflammation were treated before the limbal transplantation (LT) was applied. All participants had bilateral LSCD in this study. The surgical approach to these participants was defined according to the following criteria. First, if the patient was bilaterally affected and had a suitable living relative for harvesting the limbal tissue, an lr‑CLAL was scheduled. Second, if there was no living relative donor, limbal allografts were harvested from a cadaver, and the KLAL procedure was planned. Visual expectations and the severity of injury were taken into account during the selection of the

**Figure 1:** Conjunctivalization and irregular corneal epithelium appearance
Ozer, et al.: The outcomes of limbal allograft transplantation

preferred donors were analyzed serologically prior to tissue selection. If there were more than one living relative donor, a human leukocyte antigen (HLA) tissue match between the recipient and the donor was applied.

A clinical scoring system, based on three criteria, was used to classify LSCD severity. These criteria were determined according to the extent of limbal involvement (1–4 points), the extent of corneal surface involvement (1–4 points), and the affected or spared central corneal area within a 4 mm diameter (visual axis) (0 and 2 points). The total score was the sum of all points from the three clinical criteria. Based on the final score of the clinical grading, the stages of LSCD were classified as mild (2–4 points), moderate (5–7 points), and severe (8–10 points). According to this evaluation, two eyes (11%) had moderate LSCD and 16 eyes (89%) had severe LSCD before the LSCTs. All the procedures were done by the same operator (N.A.).

The recipient’s eye is prepared by performing a conjunctival peritomy. Then a superficial keratectomy is performed to remove abnormal epithelium and fibrovascular pannus in all LT candidates. In the lr-CLAL, two limbal grafts measuring approximately 6 mm at the limbus (3-h clock quadrants) and extending 5–8 mm posterior to the limbus are demarcated at the 12 and 6 o’clock positions. Dissection toward the cornea is extended through the limbal palisades of Vogt to ensure isolation of stem cells. The graft is then transferred to the donor’s eye, taking care to maintain the epithelial and limbal orientation of the graft. The superior and inferior quadrants of the donor’s eye are prepared as mentioned above. The 3-h-clock-sized conjunctival-limbal allografts are transplanted and secured with 10-0 nylon interrupted sutures to the recipient’s limbus, taking care that the grafts overlap the cornea 1 mm peripherally. In the KLAL, the corneoscleral rim is sectioned into equal halves. The posterior one-half to two-third of each hemisection is removed by a lamellar dissection. The acquired anterior rims are secured with interrupted sutures on the superior and inferior quadrant of the recipient’s eye. During follow-up, any comorbidities, such as glaucoma and cataract, are managed with proper surgical intervention.

All patients were followed up at the inpatient clinic daily until the leading edge of the normal corneal epithelization appeared. Afterward, follow-up visits were done regularly beginning with 1-week intervals then extended to as much as 1 month intervals after 3 months postoperatively. Concerning the severity of inflammation during the postoperative period, topical steroids, non-preserved tear drops, and antibiotics were ordered for each patient. Persistent corneal epithelial defects (PEDs) in the postoperative period were managed with AMT, temporary/permanent tarsorrhaphy, and autologous serum. In the allograft transplantation cases, systemic immunosuppressive treatment (cyclosporin A: 2.5 mg/kg) was initiated 1 month before the surgery and continued at least 18 months then gradually tapered during the follow-up. In the case of limbal allograft rejection, systemic steroid treatment was initiated during the follow-up. If the systemic immunosuppressive dosage was being tapered during a rejection incident, the dosage was increased to the initial levels and then continued until the repetition of allograft transplantation and again gradually tapered at least 18 months after the surgical procedure. Side effects from the systemic immunosuppressive treatment were followed by blood count, liver, and kidney function analyses. In the postoperative period, allograft rejection attacks, conjunctivalization recurrence due to sectoral limbal deficiency, visual acuity, and other ocular comorbidities were noted.

After healthy corneal epithelium was achieved, corneal transplantation was suggested to remove persistent central corneal opacity that restricted the visual improvement. PK was applied concurrently with the KLAL and at least 6 months after the lr-CLAL procedure. Corneal edema, endothelial rejection, glaucoma, limbal allograft rejection (defined as graft edema along with failure to maintain normal corneal epithelium and conjunctivalization recurrence), systemic immunosuppressive treatment dosage, and visual acuity were noted in PK-applied eyes during the follow-up. If LSCD recurred, an initiation of PEDs after successful LT or recurrence of conjunctivalized tissue encroaching to the corneal graft was noted, and the allograft transplantation was repeated. If there was a suitable living relative donor, lr-CLAL would be preferred; otherwise, KLAL was the procedure of choice. Eyelid defects were reconstructed before the LT. If there was any suspicion regarding improper lid function, lid reconstruction was reapplied. Despite proper treatment, some of the cases showed a recurrent cicatricial eyelid disorder during the follow-up. The primary success criteria are defined as the existence of healthy corneal epithelium and absence of fluorescein staining of abnormal corneal epithelium. The secondary success criteria are the improvement in visual acuity comparing preoperative rates.

Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software version 22 (SPSS Inc., Chicago, IL, USA). The variables were investigated using the Kolmogorov–Smirnov/Shapiro–Wilk test to determine whether or not they are typically distributed. The acquired data were reported on average, standard deviation, and percentage statistically. In categorical variability comparison, the Chi-square and Fisher’s exact tests were used. Comparisons between the groups were performed using the Student’s t-test and Mann–Whitney U-test. Cumulative survival rates of healthy epithelium and corneal graft clarity were analyzed using the Kaplan–Meier survival test. The statistical significance rate was set at $P < 0.05$.

**RESULTS**

**Limbal stem cell transplantation results in the allograft groups**

LSCT from cadavers or living relatives was applied to a total of 18 eyes of 14 patients (13 males and one female). The average
age at presentation was 35 ± 13 (13–73 years). Seven cases were in the acute group and the others were in the chronic group at presentation. Two patients (14%) had a thermal injury and 12 patients (86%) had an injury due to alkaline exposure. Two eyes (11%) had moderate LSCD and 16 eyes (89%) had severe LSCD before the limbal allograft transplantations.

Eyelid reconstruction surgery was performed for four eyes before the allograft surgery and in one eye after the allograft surgery. Of these five eyes with eyelid reconstruction, three limbal allografts failed due to PEDs in two (lr-CLAL) eyes and limbal allograft rejection in one (KLAL) eye. Limbal allograft surgery was performed in seven patients who were in the acute group at presentation, after a mean time of 8 ± 6 months (3–18 months) from injury. Lr-CLAL transplantation was performed in 16 eyes, and KLAL combined with PK was performed in two eyes as a first-line surgical option. An additional five lr-CLAL and seven KLAL transplantations were performed in nine eyes having limbal tissue failure during the follow-up. In total, 21 lr-CLAL and nine KLAL surgery procedures were performed.

The mean epithelialization time was 34 ± 29 days (3–120 days) in the lr-CLAL and 15 ± 17 days (3–51 days) in the KLAL procedure. Limbal allograft tissue rejection developed in two eyes. PK was performed in one eye due to descemetocele development due to PED 2 months after lr-CLAL surgery.

Limbal allograft rejection findings were noticed in 15 lr-CLAL tissues (15 of 21 lr-CLAL were rejected; 71%) after an average of 19 ± 19.5 months (1–69 months) from the surgery. All limbal allograft tissues that were treated with a high dosage of systemic immunosuppressives lost their vitality except two (13 of 21 lr-CLAL eventually failed after a high dosage of systemic immunosuppressive treatment; 62%). Limbal allograft rejection was observed in five KLAL tissues (five of nine KLAL; 55%) after an average of 13.4 ± 5.9 months (5–20 months) from the surgery [Table 1]. Despite treatment, limbal insufficiency developed in all cases. KLAL and lr-CLAL graft survival rates were assessed by Kaplan–Meier analysis. Postoperative survival rates of lr-CLAL tissue were 65 ±11% in the 1st year of the follow-up, 54 ±11% in the 2nd year, and 37 ±11% in the 3rd year. The survival rates of KLAL tissue were 67 ±16% and 53 ±17% in 12 and 18 months, respectively [Figure 2].

**Penetrating keratoplasty results in allograft groups**
Fifteen PKs have been performed in the limbal allograft-applied eyes either sequentially or simultaneously. Limbal allograft transplantation and PK were repeated in two eyes due to LSCD recurrence and corneal graft failure. KLAL transplantation simultaneously with PK was performed in seven eyes. The endothelial rejection was documented in two cases in 3.5 months (2–6 months) after the operation. Rejection signs and symptoms were regressed by the treatment. PK was performed sequentially in seven eyes, 9 ± 8 months (2–25 months) after the lr-CLAL transplantation. The endothelial rejection was seen in two cases in a period of 1.5 months (9–12 months) after PK, and it was regressed by the treatment.

Corneal graft failure occurred in four of seven eyes (57%) after a mean follow-up of 35 ± 25 months (2–60 months) in the KLAL group. Corneal graft failure was due to chronic endothelial cell loss in three eyes and LSCD recurrence in one eye. Corneal graft failure was seen in four of seven eyes (57%) after a mean follow-up of 33 ± 36 months (3–84 months) in the lr-CLAL group. In the lr-CLAL group, all PK procedures were applied sequentially, waiting at least 6 months after the limbal allograft transplantation. The reason for failure in four corneal grafts was recurrent epithelial defects due to limbal stem cell depletion in three eyes and endothelial failure secondary to severe postoperative IOP rise in one eye [Table 2].

Both the PK procedures were compared in terms of cumulative survival rates using Kaplan–Meier analysis. The postoperative cumulative survival rate of the corneal graft after 5 years was found to be 63 ±17% and 26 ±26% in the sequential protocol and simultaneous protocol, respectively. There was no statistically significant difference between the two groups when survival rates were compared with Mantel–Cox analysis (P = 0.75) [Figure 3]. According to our results, although the difference between the sequential protocol and simultaneous protocol in terms of graft survival was not statistically significant, it can be considered clinically significant.

During the follow-up, secondary glaucoma developed in eight of 13 eyes (62%) in which PK was applied. Glaucoma was observed in one case before the PK. IOP was regulated in all cases by topical glaucoma medications except two eyes that were treated by glaucoma drainage implant in one eye and diode laser cyclophotocoagulation in the other. During
Table 1: The preoperative and postoperative features of the chemically injured cases in whom living-related conjunctival limbal or keratolimbal allograft (lr-CLAL or KLAL) transplantation was applied

| Case number | Laterality | HLA compatibility (+/-) | Surgical indication | Surgical technique and placements of the grafts | Epithelial recovery time (days) | Donor | Follow-up time after LT (months) |
|-------------|------------|--------------------------|---------------------|-----------------------------------------------|------------------------------|-------|---------------------------------|
| 1           | OS         | -                        | PED                 | AMT                                           | 20                           | Brother | 25                              |
|             |            |                          | PED                 | Lr-CLAL (superior + inferior)                  |                              |       |                                 |
|             |            |                          | CONJ                | Lr-CLAL (superior + inferior)                  |                              |       |                                 |
| 2           | OS         | -                        | CONJ                | Lr-CLAL (superior + inferior)                  | 25                           | Brother | 129                             |
|             |            |                          | PED + CO            | KLAL (IN) + PK + ECCE                         | 6                            |       |                                 |
|             |            |                          | CONJ                | Lr-CLAL (SN)                                   | 3                            | Mother  |                                 |
| 3           | OD         | -                        | CONJ                | Lr-CLAL (superior + inferior)                  | -                            | Mother  | 134                             |
| 4           | OD         | -                        | PED                 | Eyelid reconstruction                          |                              |       |                                 |
|             |            |                          | PED                 | Lr-CLAL (superior + inferior) + AMT             | 23                           | Brother | 138                             |
|             |            |                          | PED + CO            | KLAL (inferior) + PK + AMT                     | 51                           |       |                                 |
| 5           | OD         | -                        | CONJ                | Lr-CLAL (superior + inferior) + punctum diathermy | 120                          | Mother  | 151                             |
|             |            |                          |                     | PK + ECCE + IOL                               |                              |       |                                 |
| 6           | OS         | -                        | PED + CONJ          | Lr-CLAL (superior + inferior) + AMT             | -                            | Father  | 68                              |
|             | OD         | -                        | CONJ                | Lr-CLAL (superior + inferior)                  | 46                           | Father  | 68                              |
|             |            |                          | CONJ                | KLAL (nasal + temporal) + PK                   | 10                           |       |                                 |
|             |            |                          | PED + CONJ          | Lr-CLAL (superior + inferior) + AMT             | 13                           | Father  |                                 |
| 7           | OD         | -                        | CO                  | Lr-CLAL (ST + IT)                              | 15                           | Mother  | 113                             |
|             |            |                          | PED                 | AMT                                           |                              |       |                                 |
|             |            |                          | PED + CONJ          | KLAL (nasal) + PK                              | 3                            |       |                                 |
|             |            |                          | PED                 | Lr-CLAL (ST + IT)                              | 65                           | Mother  |                                 |
| 8           | OD         | -                        | CONJ                | Lr-CLAL (ST + IT)                              | 20                           | Brother | 122                             |
|             |            |                          |                     | PK                                            |                              |       |                                 |
|             |            |                          | CONJ                | Peripheral iridectomy                           |                              |       |                                 |
|             |            |                          |                     | Ahmed valve implantation                        |                              |       |                                 |
|             |            |                          |                     | PHACO + IOL                                    |                              |       |                                 |
| 9           | OS         | +                        | PED + CONJ          | Lr-CLAL (superior + inferior) + AMT             | 73                           | Brother | 48                              |
|             | OD         | +                        | PED + CONJ          | Lr-CLAL (superior + inferior)                  | 41                           | Brother | 48                              |
|             |            |                          |                     | Semblepharon excision                           |                              |       |                                 |
|             |            |                          |                     | AMT + semblepharon excision                     |                              |       |                                 |
| 10          | OS         | -                        | CONJ                | Lr-CLAL (SN + inferior)                        | 19                           | Cousin  | 122                             |
|             |            |                          |                     | PK                                            |                              |       |                                 |
|             |            |                          | PED                 | Punctum diathermy                              |                              |       |                                 |
|             |            |                          |                     | PHACO + IOL                                    |                              |       |                                 |
|             |            |                          |                     | Tarsorrhaphy                                   |                              |       |                                 |
|             |            |                          | PED                 | KLAL (superior) + PK                            | 3                            |       |                                 |
| 11          | OD         | -                        | CONJ + PED          | Lr-CLAL (superior + inferior) + tarsorafi      | -                            | Sister  | 96                              |
|             |            |                          | CM                  | PK + ECCE + IOL                                | 41                           |       |                                 |
|             |            |                          | CONJ                | Lr-CLAL (ST + IT)                              | 19                           | Brother | 96                              |
|             |            |                          | CONJ + CO           | PK + semblepharon excision                     |                              |       |                                 |
|             |            |                          |                     | PK                                            |                              |       |                                 |
| 12          | OD         | -                        | CONJ + PED          | Lr-CLAL (superior + inferior) + AMT             | 14                           | Sister  | 75                              |
|             |            |                          |                     | PK + PHACO + IOL                               |                              |       |                                 |
|             |            |                          |                     | Lr-CLAL (ST) + punctum diathermy                |                              |       |                                 |
| 13          | OD         | +                        | CONJ                | Lr-CLAL (superior + inferior)                  | 59                           | Brother | 38                              |
|             |            |                          |                     | Eyelid reconstruction                           |                              |       |                                 |
|             |            |                          |                     | KLAL (SN)                                      | 5                            |       |                                 |

Contd...
the follow-up, one bacterial and two herpetic keratitis developed. There were no epithelialization problems after PK in the early postoperative period.

When the state of corneal epithelium of 18 eyes was evaluated at 93.8 ± 37.8 months (25–151 months) of follow-up, total conjunctivalization had occurred in four eyes (22%). In eight eyes, sectoral vascularization, which did not extend to the visual axis, was observed, and six eyes (33%) had normal corneal epithelium. All the patients who had a thermal injury (100%) showed normal corneal epithelium and increase in visual acuity at least two Snellen lines at the last follow-up visit.

There was an increase in the visual acuity in 12 of 18 eyes in the limbal allograft transplantation group after 94 ± 38 months (range, 25–151 months) of follow-up. Ten eyes (56%) exceeded the ambulatory visual acuity (≤1.0 logMAR [20/200]) level. Ambulatory vision could not be obtained in four of 13 eyes (31%) in which the sequential or simultaneous PK was performed due to a corneal scar. A two or more Snellen line gain in the best corrected visual acuity was observed in 12 eyes of 18 (67%) at the last follow-up. Of these 12 eyes, six (50%) were treated with PK sequentially with lr-CLAL, and one (8%) was treated with KLAL simultaneously with PK, five (42%) were treated with lr-CLAL sequentially with PK, and one (8%) was treated with only lr-CLAL. There was no statistically significant difference between the two procedures (KLAL simultaneously with PK versus lr-CLAL sequentially with PK) in terms of visual acuity gain (P = 0.9) [Figures 4 and 5].

Thirteen patients received systemic immunosuppressive therapy with cyclosporin A. In one of the patients, systemic

### Table 1: Contd...

| Case number | Laterality | PK surgery | LT-PK interval (months) | Post-PK graft failure yes/no (months) | Post-PK endothelial rejection yes/no (months) | Last visit BCVA | Follow-up time (months) |
|-------------|------------|------------|-------------------------|---------------------------------------|-----------------------------------------------|----------------|------------------------|
| 1           | OS         | PK (simultaneously with KLAL)   | 6                       | Yes (84)                              | No                                            | 1 mfc            | 122                    |
| 2           | OS         | PK (simultaneously with KLAL)   | 16                      | Yes (17)                              | No                                            | 151             | 122                    |
| 3           | OD         | PK (simultaneously with KLAL)   | 4                       | Yes (3)                               | No                                            | 90              | 48                     |
| 4           | OD         | PK (simultaneously with KLAL)   | 12                      | No                                    | No                                            | 75              | 122                    |
| 5           | OD         | PK + ECCE + IOL (sequentially with lr-CLAL) | 14                      | Yes (26)                              | No                                            | 90              | 122                    |
| 6           | OD         | PK (simultaneously with KLAL)   | 12                      | No                                    | No                                            | 75              | 122                    |
| 7           | OD         | PK (simultaneously with KLAL)   | 15                      | Yes (2)                               | No                                            | 75              | 122                    |
| 8           | OD         | PK (sequentially with lr-CLAL)  | 4                       | Yes (3)                               | No                                            | 75              | 122                    |
| 9           | OD         | PK (sequentially with lr-CLAL)  | 2                       | No                                    | Yes (9)                                       | 96              | 122                    |
| 10          | OD         | PK (sequentially with lr-CLAL)  | 16                      | Yes (17)                              | No                                            | 151             | 122                    |
| 11          | OD         | PK + ECCE + IOL (sequentially with lr-CLAL) | 4                       | Yes (3)                               | No                                            | 75              | 122                    |
| 12          | OD         | PK + ECCE + IOL (sequentially with lr-CLAL) | 12                      | No                                    | No                                            | 75              | 122                    |
| 13          | OD         | PK (sequentially with lr-CLAL)  | 4                       | No                                    | Yes (12)                                      | 151             | 122                    |
| 14          | OD         | PK + ECCE + IOL (sequentially with lr-CLAL) | 14                      | Yes (26)                              | No                                            | 75              | 122                    |

PK: Penetrating keratoplasty, LT: Limbal transplantation, BCVA: Best corrected visual acuity, OS: Oculus sinister, OD: Oculus dexter, KLAL: Keratolimbal allograft, ECCE: Extracapsular cataract extraction, IOL: Intraocular lens, lr-CLAL: Living-related conjunctival limbal allograft, HM: Hand motion, cmfc: Centimeter finger counting, mfc: Meter finger counting
cyclosporine A (CSA) therapy was discontinued due to the development of renal toxicity. In other cases, there were no CSA-related side effects. Systemic cyclosporine treatment was used for a mean duration of 59 ± 30 months (range, 19–122 months). All but one limbal allograft rejection cases were under the treatment of systemic immunosuppression during rejection. The mean systemic immunosuppression dosage was 150 mg/day (75–200 mg/day) level in lr‑CLAL tissue when limbal allograft rejection was observed and at 87.5 mg/day (0–200 mg/day) level when KLAL rejection was observed.

**DISCUSSION**

We have evaluated the outcomes of limbal allograft transplantation in a group of patients who had bilateral LSCD due to the chemical injury. The survival rates of the limbal allografts during the follow-up were compared. In addition, the clear corneal allograft maintenance rates between the sequentially and simultaneously applied PK procedures were compared. We also evaluated the most recent LSCT methods and their success rates compared to conventional LSCT procedures. In this study, the existence of normal corneal epithelium and improvement in visual acuity were accepted as the surgical success criteria.

Limbal allograft surgery procedures are not as successful as the limbal autograft procedure. In bilaterally affected cases of ocular surface damage, limbal allograft transplantation is warranted. There is an immunological failure risk of allografts, and the risk of rejection is inevitable at the end. The length of the follow-up period, as seen from the literature, is directly associated with limbal graft survival. Santos *et al*. found that the cumulative limbal allograft survival rate in lr‑CLAL eyes was applied 33% at the end of 33-month of follow-up. Gomes *et al*. stated that surgical success was achieved in six of 10 eyes (60%) in which AMT combined with lr‑CLAL transplantation was applied at the end of 19 months of follow-up, and only <75% HLA tissue compatibility cases received CSA treatment. Javadi *et al*. applied the lr‑CLAL procedure in 32 eyes and KLAL procedure in 40 eyes. At the end of the 40-month postoperative follow-up, the lr‑CLAL survival rate was 39.1% and the KLAL survival rate was 80.7%. The low rate of success in the lr‑CLAL group was associated with the lack of HLA matching preoperatively and continuation of systemic immunosuppressive treatment for a short time (1 year). Javadi *et al*. indicated that HLA tissue compatibility and long-term systemic immunosuppressive treatment are essential factors for lr‑CLAL survival.

Similarly, in our study, we took the graft from the most compatible donor if there was more than one donor, and HLA tissue sampling was done preoperatively in all cases. The cumulative survival rate of 21 lr‑CLAL tissue cases at the 1st, 2nd, and 3rd year postoperative was 65%, 54%, and 37%, respectively. Systemic cyclosporine treatment was given to all patients. Even if all cases were under the systemic immunosuppressive treatment, only two tissues (13%) were able to maintain their viability after the rejection treatment. In actuality, the immunosuppressive dosage at the time when the rejection signs emerged was 150 mg/day (75–200 mg/day), and this may be a sign that systemic immunosuppression remains inadequate with a single drug usage. Likewise, today, it is said that triple immunosuppressive therapy is more efficacious.

In studies related to KLAL, success rates ranged from 33% to 84% in the literature. Solomon *et al*. showed that KLAL survival rates had decreased progressively long-term, and this rate was 76% in the first postoperative year but decreased to 24% in the 5th year. In another study, Ilari and Daya stated that limbal allograft tissue survival rates were 54% in the 1st postoperative year, 33% in the 2nd year, and 27% in the
In our study, graft failure developed postoperative year, respectively. It seems that allo-CLET's study, only high-risk patients reported that in a series of simultaneous procedures, corneal clarity rates were found to be 48% in the 1st postoperative year and 54% at the 2nd postoperative year, respectively. We also followed up for an average of 2 years in the majority of the cases. Only one study compared the outcome of allo-CLET and an established procedure, KLAL, in a patient who underwent LSCT in both the eyes. The allograft rejection rate and the ocular stability success of the former procedure were superior to the latter one.

After the first introduction of the SLET procedure, the majority of the published records about autologous-SLET transplantation are up to date. This procedure is thought to be a good alternative for conjunctival-limbal autograft transplantation in terms of small-donor tissue requirement, thus avoiding the potential risk of LSCD development in the donor’s eye. The only allo-SLET experience was reported by Bhalekar et al. about a case of immunological rejection 4 months after an allogeneic SLET for bilateral LSCD. The researchers emphasized the need for continued immunosuppression in limbal allografts including SLET. In our results, the survival rate of the KLAL and lr-CLAL tissue was 53 ± 17% in the postoperative 18 months and 54% at the 2nd postoperative year, respectively. It seems that allo-CLET has more favorable results in terms of allograft viability, compared to the conventional LSCT procedures. The reason for the decreased incidence of immunological rejection in CLET compared to conventional limbal allograft transplantation procedures (KLAL and lr-CLAL) has been speculated, as the Langerhans cells are not cultured in the composite graft.

An inflamed and vascularized recipient bed is known to increase the risk of rejection of corneal grafts. Therefore, it is recommended that before deciding the time of corneal transplantation, ocular surface stabilization should be maintained, which is going to occur at least 3 months after LSCT. Tsubota et al. reported that in a series of studies consisting of nine eyes in which KLAL transplantation was done simultaneously with PK, five of nine donor corneas remained clear at the end of 12 months. In 2002, Solomon reported that in a series of simultaneous procedures, corneal clarity rates were found to be 48% in the 1st year postoperative and 14% in the 3rd year. In our study, graft failure developed in four of seven eyes (57%) in 35 ± 25 months (2-60 months) after KLAL transplantation simultaneously with PK. The
reason for graft failure was due to the chronic loss of endothelium in 50% of cases. The corneal clarity rate in the 5th postoperative year was 26%. Shimazaki et al. applied simultaneous PK in 15/32 eyes and sequential PK in 6/32 eyes in their study to compare the two protocols in terms of their effectiveness. The incidence of endothelial rejection was higher in the simultaneous procedure group (0%–53.3%). In our study, the survival rate of corneal allograft at the 5th postoperative year was low in the simultaneous procedure compared to the staged procedure, but it was not statistically significant (26 ± 26% vs. 63 ± 17%) ($P = 0.75$). The corneal endothelial rejection attacks occurred in two corneal grafts for each procedure. The postoperative rejection developed in the early period in the simultaneous procedure compared to the staged procedure (3.5 months to 10.5 months). As a result, the staged procedure was found to be more successful than the simultaneous procedure, but statistically significant differences could not be detected between the two groups due to the lack of a sufficient number of patients.

In the studies in which conventional limbal allograft transplantation was applied, the increase in visual acuity ranged from 31% to 67% in the literature. In CLET procedures, a gain of two or more Snellen lines in the best corrected visual acuity was observed in up to 62% of cases. In our study, at the end of 93.8 ± 37.8 months (range, 25–151 months) of follow-up, the visual acuity level increased in 12 eyes (67%) in which the limbal allograft transplantation was applied. The ambulatory visual acuity level was achieved ($\leq 1.0$ logMAR [20/200]) in 10 eyes (56%). In addition, a gain of two or more Snellen lines in the best corrected visual acuity was observed in 12 of 18 eyes (67%) at the last follow-up, and there was no significant difference between the KLAL and lr-CLAL.

In the literature, the rate of postoperative glaucoma ranged from 26% to 32%. In our study, postoperative glaucoma developed in one of 18 eyes (6%) before the PK and eight of 13 eyes (62%) after the PK. Additional surgical procedures were required in three eyes (23%) in which the IOP was unable to be controlled with topical medications after PK. It has been reported that postoperative bacterial keratitis rates range from 8 to 14% in the literature. In our study, herpetic keratitis was seen in two eyes (11%), and bacterial keratitis was seen in one eye (6%).

As a result, limbal allograft transplantation is still the most crucial treatment option in bilaterally severe LSCD. Suppression of inflammation in the preoperative period and awareness of the risk of secondary glaucoma and performing eyelid reconstruction as needed are essential factors for surgical success. The success rate of surgery would decrease with increasing duration of follow-up in allograft LT procedures even if the risk factors were removed. The staged procedure is much more convenient than the simultaneous procedure in terms of corneal allograft clarity maintenance in limbal allograft employed eyes. Under the single-dose immunosuppressive therapy during follow-up regardless of dosage, the rejection of a limbal allograft may occur. One should be careful in terms of infectious keratitis and secondary glaucoma in the follow-up period.

**Acknowledgments**

The authors would like to thank Fedai Abi, who is the former secretary of the cornea section, for supporting us during the collection of data.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Cotsarelis G, Cheng SZ, Dong G, Sun TT, Lavker RM. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: Implications on epithelial stem cells. Cell 1989;57:201-9.
2. Tseng SC. Regulation and clinical implications of corneal epithelial stem cells. Mol Biol Rep 1996;23:47-58.
3. Dua HS, Azaiza-Blanco A. Limbal stem cells of the corneal epithelium. Surv Ophthalmol 2000;44:415-25.
4. Dua HS, Azaiza-Blanco A. Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol 1999;83:414-9.
5. Holland EJ. Epithelial transplantation for the management of severe ocular surface disease. Trans Am Ophthalmol Soc 1996;94:677-743.
6. Pellegrini G, Traverso CE, Franzl AT, Zingirian M, Cancetta R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet 1997;349:990-3.
7. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010;363:147-55.
8. Tan DT, Ficker LA, Buckley RJ. Limbal transplantation. Ophthalmology 1996;103:29-36.
9. Thoft RA, Friend J. Biochemical transformation of regenerating ocular surface epithelium. Invest Ophthalmol Vis Sci 1977;16:14-20.
10. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. Ophthalmology 1989;96:709-22.
11. Jenkins C, Tuft S, Liu C, Buckley R. Limbal transplantation in the management of chronic contact-lens-associated epithelialopathy. Eye (Lond) 1993;7(Pt 5):629-33.
12. Morgan S, Murray A. Limbal autotransplantation in the acute and chronic phases of severe chemical injuries. Eye (Lond) 1996;10 (Pt 3):349-54.
13. Moldovan SM, Borderie V, Baudrimont M, Laroche L. Treatment of unilateral limbal stem cell deficiency syndrome by limbal autograft. J Fr Ophthalmol 1999;22:302-9.
14. Rao SK, Rajagopal R, Sitalakshmi G, Padmanabhan P. Limbal autografting: Comparison of results in the acute and chronic phases of ocular surface burns. Cornea 1999;18:164-71.
15. Daya SM, Ilari L. Living related conjunctival limbal allograft for the treatment of stem cell deficiency. Ophthalmology 2001;108:126-34.
16. Tsai RJ, Tseng SC. Human allograft limbal transplantation for corneal surface reconstruction. Cornea 1994;13:389-400.
17. Tsibota K, Toda I, Saito H, Shinozaki N, Shimazaki J. Reconstruction of the corneal epithelium by limbal allograft transplantation for severe ocular surface disorders. Ophthalmology 1995;102:1486-96.
18. Santos MS, Gomes JA, Hofting-Lima AL, Rizzo LV, Romano AC, Belfort R Jr. Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. Am J Ophthalmol 2005;140:223-30.
19. Gomes JA, dos Santos MS, Cunha MC, Mascaro VL, Barros Jde N, de Sousa LB. Amniotic membrane transplantation for partial and total...
limbal stem cell deficiency secondary to chemical burn. Ophthalmology 2003;110:466-73.
20. Javadi MA, Jafarienasab MR, Feizi S, Karimian F, Negahban K. Management of mustard gas-induced limbal stem cell deficiency and keratitis. Ophthalmology 2011;118:1272-81.
21. Djallilian AR, Bhasin AK, Holland EJ. Postoperative management of ocular surface reconstruction. In: Kraemer JH, Mannis MJ, Holland EJ, editors. Cornea. 3rd ed. Philadelphia: Elsevier-Mosby; 2011. p. 1745-53.
22. Cauchy PA, Ang GS, Azaara-Blanco A, Burr JM. A systematic literature review of surgical interventions for limbal stem cell deficiency in humans. Am J Ophthalmol 2008;146:251-9.
23. Solomon A, Ellis P, Anderson DF, Touhami A, Grueterich M, Espana EM, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology 2002;109:1159-66.
24. Ilari L, Daya SM. Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. Ophthalmology 2002;109:1278-84.
25. Yin J, Jurkunas U. Limbal stem cell transplantation and complications. Semin Ophthalmol 2018;33:134-41.
26. Mishan MA, Yaseri M, Baradaran-Rafii A, Kanavi MR. Systemic review and meta-analysis investigating autograft versus allograft cultivated limbal epithelial transplantation in limbal stem cell deficiency. J Ophthalmol 2019;2019:109:1159-66.
27. Shortt AJ, Secker GA, Notara MD, Limb GA, Khaw PT, Tuft SJ, et al. Transplantation of ex vivo cultured limbal epithelial stem cells: A review of techniques and clinical results. Surv Ophthalmol 2007;52:483-502.
28. Baylis O, Figueiredo F, Henein C, Lako M, Ahmad S. 13 years of cultured limbal epithelial cell therapy: A review of the outcomes. J Cell Biochem 2011;112:993-1002.
29. Zhao Y, Ma L. Systematic review and meta-analysis on transplantation of ex vivo cultivated limbal epithelial stem cell on amniotic membrane in limbal stem cell deficiency. Cornea. 2015;34:592-600.
30. Haagdorens M, Van Acker SI, Van Gerwen V, Ní Dhubhghaill S, editors. Corneal Surgery: Theory, Technique, and Tissue. St. Louis: Mosby; 1999. p. 508.
31. Crossdale CR, Schwartz GS, Mallin JV, Holland EJ. Keratolimbal allograft: Recommendations for tissue procurement and preparation by eye banks, and standard surgical technique. Cornea 1999;18:52-8.
32. Vazirani J, Ali MH, Sharma N, Gupta N, Mittal V, Atallah M, et al. Autologous simple limbal epithelial transplantation for unilateral limbal stem cell deficiency: Multicentre results. Br J Ophthalmol 2016;100:1416-20.
33. Mittal V, Jain R, Mittal R, Vashist U, Narang P. Successful management of severe unilateral chemical burns in children using simple limbal epithelial transplantation (SLET). Br J Ophthalmol 2016;100:1102-8.
34. Basu S, Sureka SP, Shanhag SS, Kethiri AR, Singh V, Sangwan VS. Simple limbal epithelial transplantation: Long-term clinical outcomes in 125 cases of unilateral chronic ocular surface burns. Ophthalmology 2016;123:1000-10.
35. Dua HS, Miri A, Alomar T, Yeung AM, Said DG. The role of limbal stem cells in corneal epithelial maintenance: Testing the dogma. Ophthalmology 2009;116:856-63.
36. Aravane C, Bozkurt K, Chuehanich P, Supiyaphun C, Yu F, Deng SX. Classification of limbal stem cell deficiency using clinical and confocal grading. Cornea 2019;38:1-7.
37. Fogla R, Padmanabhan P. Deep anterior lamellar keratoplasty combined with autologous limbal stem cell transplantation in unilateral severe chemical injury. Cornea 2005;24:421-5.
38. Omoto M, Shimmura S, Hatou S, Ichihashi Y, Kawakita T, Tsubota K. Simultaneous deep anterior lamellar keratoplasty and limbal allograft in bilateral limbal stem cell deficiency. Jpn J Ophthalmol 2010;54:537-43.
39. Ang LP, Sotozono C, Koizumi N, Suzuki T, Iatomi T, Kinoshita S. A comparison between cultivated and conventional limbal stem cell transplantation for Stevens-Johnson syndrome. Am J Ophthalmol 2007;143:178-80.
40. Sangwan VS, Basu S, MacNeil S, Balasubramanian D. Simple limbal epithelial transplantation (SLET): A novel surgical technique for the treatment of unilateral limbal stem cell deficiency. Br J Ophthalmol 2012;96:931-4.
41. Bhalekar S, Basu S, Sangwan VS. Successful management of immunological rejection following allogeneic simple limbal epithelial transplantation (SLET) for bilateral ocular burns. BMJ Case Rep 2013;2013:2013:bcr2013009051.
42. Gottsch JD, Jakobs FM, WJ, Regrafting. FS, editors. Corneal Surgery: Theory, Technique, and Tissue. St. Louis: Mosby; 1999. p. 508.
43. Trivedi S, Tsubota K. Keratolimbal allograft transplantation in limbal stem cell deficiency. Cornea. 2016;35:1-10.
44. Aravena C, Bozkurt K, Chuehanich P, Supiyaphun C, Yu F, Deng SX. Classification of limbal stem cell deficiency using clinical and confocal grading. Cornea 2019;38:1-7.
45. Tsubota K, Satake Y, Kaido M, Shinozaki N, Shimmura S, editors. Cornea. 3rd ed. Philadelphia: Elsevier-Mosby; 2011. p. 1745-53.
46. Cauchy PA, Ang GS, Azaara-Blanco A, Burr JM. A systematic literature review of surgical interventions for limbal stem cell deficiency in humans. Am J Ophthalmol 2008;146:251-9.
47. Solomon A, Ellis P, Anderson DF, Touhami A, Grueterich M, Espana EM, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology 2002;109:1159-66.
48. Ilari L, Daya SM. Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. Ophthalmology 2002;109:1278-84.
49. Yin J, Jurkunas U. Limbal stem cell transplantation and complications. Semin Ophthalmol 2018;33:134-41.
50. Mishan MA, Yaseri M, Baradaran-Rafii A, Kanavi MR. Systemic review and meta-analysis investigating autograft versus allograft cultivated limbal epithelial transplantation in limbal stem cell deficiency. Int J Ophthalmol 2019;39:2685-96.
51. Shortt AJ, Secker GA, Notara MD, Limb GA, Khaw PT, Tuft SJ, et al. Transplantation of ex vivo cultured limbal epithelial stem cells: A review of techniques and clinical results. Surv Ophthalmol 2007;52:483-502.
52. Baylis O, Figueiredo F, Henein C, Lako M, Ahmad S. 13 years of cultured limbal epithelial cell therapy: A review of the outcomes. J Cell Biochem 2011;112:993-1002.
53. Zhao Y, Ma L. Systematic review and meta-analysis on transplantation of ex vivo cultured limbal epithelial stem cell on amniotic membrane in limbal stem cell deficiency. Cornea. 2015;34:592-600.
54. Haagdorens M, Van Acker SI, Van Gerwen V, Ní Dhubhghaill S, Koppen C, Tassignon MJ, et al. Limbal stem cell deficiency: Multicentre results. Br J Ophthalmol 2016;100:1416-20.
55. Vazirani J, Ali MH, Sharma N, Gupta N, Mittal V, Atallah M, et al. Autologous simple limbal epithelial transplantation for unilateral limbal stem cell deficiency: Multicentre results. Br J Ophthalmol 2016;100:1416-20.
56. Mittal V, Jain R, Mittal R, Vashist U, Narang P. Successful management of severe unilateral chemical burns in children using simple limbal epithelial transplantation (SLET). Br J Ophthalmol 2016;100:1102-8.